載入中
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
前收盤價
US$5.68
−US$0.40 · -6.58%
盤前
US$6.7301
+US$1.0501 · +18.49%
10月8日 上午7:39 ET
盤中時間採用ET。市場資料可能有所延遲。
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
日內區間
目前US$5.68
52週區間
目前US$5.68
盤中時間採用ET。市場資料可能有所延遲。
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
日內區間
目前US$5.68
52週區間
目前US$5.68
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1637.98萬 USD | 1016.72萬 USD | 719.9萬 USD | 668.1萬 USD | 687.3萬 USD |
| 銷貨成本 | 478.74萬 USD | 346.81萬 USD | 281.7萬 USD | 366萬 USD | 392.1萬 USD |
| 毛利 | 1159.24萬 USD | 669.91萬 USD | 438.2萬 USD | 302.1萬 USD | 295.2萬 USD |
| 研究與開發 | 2095.65萬 USD | 1615.04萬 USD | 1437.7萬 USD | 1469萬 USD | 1527.7萬 USD |
| 銷售、一般及管理費用 | 3261.21萬 USD | 2202.33萬 USD | 1862.1萬 USD | 1793.3萬 USD | 1796.6萬 USD |
| 營業費用 | 5356.86萬 USD | 3817.37萬 USD | 3299.8萬 USD | 3514.7萬 USD | 3324.3萬 USD |
| 利息收入 | 108.87萬 USD | 136.71萬 USD | 164.2萬 USD | 104.97萬 USD | 20.32萬 USD |
| 利息支出 | — | — | 77萬 USD | 16.71萬 USD | 6.64萬 USD |
| 折舊和攤銷 | 56.98萬 USD | 93.6萬 USD | 92.9萬 USD | 160.4萬 USD | 187.9萬 USD |
| 營業利益 | −4197.62萬 USD | −3147.46萬 USD | −2861.6萬 USD | −3212.6萬 USD | −3029.1萬 USD |
| 淨利 | −4331.52萬 USD | −2648.05萬 USD | −2856.9萬 USD | −2866.9萬 USD | −3069.9萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$11.00
上漲空間 93.66%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2019年10月16日 | 1:10 | — | — |
已生效 2019年10月16日
1:10
報告持有此股票曝險的交易所交易基金。
Invesco NASDAQ Future Gen 200 ETFQQQS
Dimensional - International Core Equity 2 ETFDFIC
State Street SPDR Portfolio Europe ETFSPEUAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
